Search Results

You are looking at 1 - 10 of 25 items for :

  • nuclear program x
  • Haematology, Oncology x
Clear All
Open access

Zvonka Slavec, Simona Gaberscek and Ksenija Slavec

. Kocijančič A, Mrevlje F.(ed.). Interna medicina . (Internal medicine), Ljubljana: EWO, DZS; 1993. 1145 pages. Avsec Letonja D, Vončina J. Transplantacijska dejavnost: donorski program. 1, Organi . (Transplant activity - a donor programme). Ljubljana: Zavod RS za presaditev organov in tkiv Slovenija-transplant; 2003. 146 pages. Hodolic M. Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011; 45 : 17-21.

Open access

Hanan R. Nassar, Alfred E. Namour, Hanan E. Shafik, Amr S. El Sayed, Samar M. Kamel, Manar M. Moneer and Nadia I. Zakhary

References [1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1. 2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer [available from], <http:// www.globocan.iarc.fr/factsheets/cancers/breast. asp>; 2010 [accessed on 24.09.2012]. [2] The National Cancer Registry Program of Egypt (NCRPE). Reports and Statistics: Aswan, Damietta & El-Minia [available from], <http://www. cancerregistry.gov.eg/reports.aspx> [accessed 5

Open access

E. Veniou, I. Sofatzis, I. Kalantzis, M. Karakosta, M. Logothetis, E. Lianos and N. Ziras

these trials and possible co-existence of confounding or discriminatory factors should be taken into account. Furthermore, as indicated in Table 1 , a universally accepted definition of the metabolic syndrome is missing and different criteria have been adopted by several groups [ 8 – 10 ]. Table 1 Definitions of the Metabolic Syndrome Risk Factors National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) (8) ≥ 3 of 5 criteria necessary WHO 1999 (9) Impaired glucose regulation or hyperinsulinemia and ≥ 2 of criteria necessary

Open access

R. Sklavenitis-Pistofidis, T. Koletsa, A. Lazaridou and A. Goulas

domain. PIP 3 : Phosphatidylinositol 3,4,5-triphosphate. PKC: Protein kinase C. Lyn, Syk: Src-family tyrosine kinases. BLNK: B-cell linker protein. PLCγ2: Phospholipase C γ-2. NF-κB: Nuclear factor kappa B. Btk contains five domains through which it interacts with other proteins of the B-cell receptor signalling pathway, leading to PLCγ2 and eventually, NF-κB activation. PH is used for binding to PIP 3 , which recruits Btk to the plasma membrane; TH contains a zinc-finger motif; SH2 is used for docking to phosphorylated tyrosine residues on other proteins, allowing

Open access

Mokhtar M Galila, Ebeid FS Fatma, Ishak AI Sherif, Ragab A Iman and Yousef AS Khaled

poor responders’ osteosarcoma including immunomodulation. Improvements in clinical outcomes may largely been attributable to a multidisciplinary team-based approach consequently at 2014, a multidisciplinary teamwork (paediatrician, orthopaedic surgeon, and nuclear medicine physician) evolved and finally succeeded in establishment of a weekly multidisciplinary solid tumour clinic at Paediatric haematology/ oncology clinic to improve the management and outcome of paediatric bone tumour through better communication and rapid decisions. Furthermore in the developing

Open access

’S BELIEFS AND ATTITUDES IN THE PREFECTURE OF SERRES TOWARDS BREAST CANCER SCREENING USING THE HEALTH BELIEF MODEL Tragouda S. 1 , Trigoni M. 2 , Paraskeuopoulou S. 3 1 . Post-graduate student of the Healthcare Management post-graduate studies program (Hellenic Open University) 2 . Head of Department of Social Services University Hospital of Crete, Consultant Professor of Hellenic Open University, Greece 3 . Consultant Professor of Hellenic Open University, Greece Introduction : Breast cancer is the most common form of neoplasm in women and the most frequently

Open access

Bozidar Casar, Maria do Carmo Lopes, Advan Drljević, Eduard Gershkevitsh and Csilla Pesznyak

medicine examinations and 5 million radiotherapy courses undertaken annually. Such tremendous development has triggered demands and need for more highly educated and well trained medical physicists. Introduction of formal systems for education and clinical training became crucial and many universities in Europe offer academic programmes in medical physics. However, there is still a lack of accredited clinical training programs in the majority of countries in Europe. Although international and European professional medical physics organizations together with European

Open access

Bartlomiej Szynglarewicz, Piotr Kasprzak, Przemyslaw Biecek, Agnieszka Halon and Rafal Matkowski

Introduction The development of imaging techniques and the widespread adoption of screening programs resulted in dramatically increased incidence of ductal carcinoma in situ (DCIS), which currently accounts for about 20 – 25% of newly diagnosed breast cancer cases. 1 The most common clinical presentation of DCIS are mammographically visible microcalcifications. Although being present in about 30% of all breast cancers and in approximately 55% of non-palpable breast malignancies, they are responsible for the detection of 85 – 95% of cases of DCIS by

Open access

Tanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Cemazar, Laurence Le Moyec, Antoine F. Carpentier, Philippe Savarin and Janja Ocvirk

-Herttuala S, et al. Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res 2003; 63: 3195-201. Griffin JL Lehtimäki KK Valonen PK Gröhn OH Kettunen MI Ylä-Herttuala S et al Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death Cancer Res 2003 63 3195 201 26 Opstad KS, Bell BA

Open access

Natale Quartuccio, Giorgio Treglia, Marco Salsano, Maria Vittoria Mattoli, Barbara Muoio, Arnoldo Piccardo, Egesta Lopci and Angelina Cistaro

References 1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-43. 2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21: 320-5. 3. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-52. 4. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic